^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + BI 1701963 (SOS1 inhibitor, pan-KRAS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan
Published date:
04/27/2020
Excerpt:
In this work, we present combination data for the clinical candidate BI 1701963 with the MEK inhibitor trametinib and, in addition, with irinotecan, a key component of the widely used CRC standard-of-care chemotherapy treatment regimen. Both combinations show strong in vivo efficacy in tumor mouse models. The SOS1::KRAS/MEK inhibitor combination results in anti-tumor effects in a broad spectrum of KRAS-mutated CRC PDX models.
DOI:
10.1158/1538-7445.AM2020-1091
